The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
 
Shunji Takahashi
Honoraria - Eisai
Research Funding - Eisai
 
Naomi Kiyota
Honoraria - Eisai
Research Funding - Boehringer Ingelheim; Eisai; Ono Pharmaceutical
 
Tomoko Yamazaki
No Relationships to Disclose
 
Naoko Chayahara
No Relationships to Disclose
 
Kenji Nakano
Consulting or Advisory Role - GlaxoSmithKline; Novartis
Speakers' Bureau - Eisai; Merck Serono; Novartis
Travel, Accommodations, Expenses - Merck Serono; Novartis
 
LINA INAGAKI
No Relationships to Disclose
 
Kazuhisa Toda
No Relationships to Disclose
 
Tomohiro Enokida
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Eisai
Speakers' Bureau - Eisai
Research Funding - Eisai
 
Yoshinori Imamura
No Relationships to Disclose
 
Tatsuya Sasaki
Employment - Eisai
 
Takuya Suzuki
Employment - Eisai
 
Katsuki Fujino
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Corina Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Otsuka
Consulting or Advisory Role - Bayer; MSD; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)